Survodutide

Generic Name: Survodutide

Clinical Trials

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Survodutide
Drug: Semaglutide

First Posted Date: 2024-12-20

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06745284

Locations: 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase 3

Recruiting

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis

Interventions: Drug: Survodutide
Drug: Placebo

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1800

Registration Number: NCT06632444

Locations: 🇺🇸
Arizona Liver Health-Chandler-68733, Chandler, Arizona, United States
🇺🇸
The Institute for Liver Health, LLC, Tucson, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States

and more 444 locations

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase 3

Recruiting

Conditions: Metabolic Dysfunction Associated Steatohepatitis

Interventions: Drug: Survodutide
Drug: Placebo matching survodutide

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1590

Registration Number: NCT06632457

Locations: 🇨🇳
Changzhou Third People's Hospital, Changzhou Shi, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇺🇸
The Institute for Liver Health, LLC, Tucson, Arizona, United States

and more 419 locations

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Survodutide
Drug: Bupropion
Drug: Caffeine
Drug: Midazolam

First Posted Date: 2024-08-21

Last Posted Date: 2025-04-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06564441

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: survodutide

First Posted Date: 2024-07-09

Last Posted Date: 2025-04-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06492135

Locations: 🇨🇳
Shanghai Central Hospital of Xuhui District, Shanghai, China

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BI 456906
Drug: BI 1820237
Drug: Placebo for BI 1820237
Drug: Placebo for BI 456906

First Posted Date: 2024-04-08

Last Posted Date: 2025-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT06352424

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Recruiting

Conditions: Renal Impairment
Healthy

Interventions: Drug: BI 456906

First Posted Date: 2024-04-08

Last Posted Date: 2025-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT06352411

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity
Non-Alcoholic SteatoHepatitis (NASH)

Interventions: Drug: Placebo
Drug: Survodutide

First Posted Date: 2024-03-13

Last Posted Date: 2025-04-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 218

Registration Number: NCT06309992

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Gastroenterology and Liver Research LLC, Houston, Texas, United States
🇺🇸
Accurate Clinical Research, Inc., Humble, Texas, United States

and more 35 locations

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: survodutide
Drug: Placebo matching BI 456906

First Posted Date: 2024-01-22

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 307

Registration Number: NCT06214741

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Beijing Pinggu Hospital, Beijing, China

and more 27 locations

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Drug: BI 456906
Drug: Placebo to BI 456906
Drug: Moxifloxacin
Drug: Placebo to moxifloxacin

First Posted Date: 2024-01-11

Last Posted Date: 2025-03-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 110

Registration Number: NCT06200467

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy